List
The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.
-
Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective,Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage
SBC: NEUROP, INC. Topic: 102Abstract Subarachnoid hemorrhageSAHremains a serious source of neurological morbiditywith approximatelycases reported in the US each yearDespite advances in treating the initial and subsequent bleedspost surgical clipping of the aneurysm is associated with a significant risk of delayed cerebral ischemiaDCIThese events typically occur within the firstdays after aneurysmal rupture and DCI remains th ...
SBIR Phase II 2017 Department of Health and Human Services -
Advanced therapeutic for Parkinson's Disease
SBC: INHIBIKASE THERAPEUTICS Topic: 105Parkinson s DiseasePDis a progressive neurodegenerative disorder that affectsmillion patient in the U Sannually andtomillion people worldwidePD is characterized by disorders of movementwhich are caused by the progressive loss of dopamine neurons in the substantia nigra pars compactaSNpcand autonomic dysfunctionanxietydepressionsleep disorders and cognitive impairment that are due to the degenerati ...
SBIR Phase II 2017 Department of Health and Human Services -
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II
SBC: MBC Pharma, Inc. Topic: NCIProject Summary AbstractThe overall aim of this project is to further develop a novel gemcitabine ibandronate conjugate alone and or as part of a combination therapy for the treatment of osteosarcoma and associated metastasesThe conjugate consists of chemically linked anticancer antimetabolite Gemcitabine and the bone homing bisphosphonate IbandronateThe novel conjugate directly addresses the limi ...
SBIR Phase II 2017 Department of Health and Human Services -
Advanced PML antiviral
SBC: INHIBIKASE THERAPEUTICS Topic: NIAIDInhibikase Therapeutics is a clinical stagebiopharmaceutical company that has developed a hosttargeted mechanism of action to treat AIDS related and drug induced progressive multifocal leukoencephalopathyPMLPML is a demyelinating disease of the central nervous system and was rarely seen clinically until the era of the HIV epidemic began in the midsDuring the height of the epidemicthe rate of PML o ...
SBIR Phase II 2017 Department of Health and Human Services -
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP
SBC: PharmaIN Corporation Topic: NHLBIABSTRACTThis application is seeking funding specifically for ChemistryManufacturingand ControlCMCof scale up production of long acting atrial natriuretic peptidedANPand its protected graft co polymerPGCexcipient for use in heart failureHFtreatmentThe extrinsic merit of this project will be the availability of cGMP grade PGC for use in prolonging the half life of various peptide drugs that are in p ...
SBIR Phase II 2017 Department of Health and Human Services -
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis
SBC: VIRTICI LLC Topic: NIAIDOur goal is to develop VTC MSas a novel tolerance inducing therapeutic to treat Multiple SclerosisMSMS is the most common demyelinating disorder of the Central Nervous SystemCNSaffecting approximatelymillion people worldwide andin the US aloneCurrent and developing treatment of MS relies mainly on immuno suppression and modulation to reduce inflammatory symptoms creating a significant need for new ...
SBIR Phase II 2017 Department of Health and Human Services -
Kinetic Phenotype Discovery Informatics for Neurological Diseases
SBC: DRVISION TECHNOLOGIES LLC Topic: 101Project Summary Neurological disorders significantly outnumber diseases in other therapeutic areas and are growing in incidence faster than any other disease classesHoweverthe pharmaceutical industry has been unsuccessful in coming up with effective drugsA big factor in these failures has been a lack of adequate model systems for fundamental disease understanding affecting both diagnosis and treat ...
SBIR Phase II 2017 Department of Health and Human Services -
A Novel Peptide Therapeutic for Obesity
SBC: VIRTICI LLC Topic: 300Project Summary The goal of this project is to develop a novel peptide therapeuticVTC Gfor the treatment of obesityTodayone third of adults in the United StatesUSare obesewith an estimated annual healthcare burden of approximately $billionByit is projected that overof adults in the US will be obese with a yearly healthcare burden expected to exceed $billionwhich will account for approximatelyof th ...
SBIR Phase II 2017 Department of Health and Human Services -
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer
SBC: METACLIPSE THERAPEUTICS CORPORATION Topic: 102The worldwide incidence of breast cancer ismillionTriple negative breast cancersTNBCaccount forof total breast cancer casesworldwideAnnuallyovernew cases of TNBC are diagnosed in the US aloneThe treatment options for TNBC patients are limitedTriple negative breast cancerTNBCincludes breast cancers that lack estrogen receptorprogesterone receptorand HERproteinsLack of known targets and patient to p ...
SBIR Phase II 2017 Department of Health and Human Services -
Micropatterned surfaces for minimizing pediatric gastrostomy tube complications
SBC: Sharklet Technologies Inc. Topic: NICHDSummary In a variety of diseases and conditions when oral feeding is impossibleenteral feeding through percutaneous gastrostomyPGis necessary to provide long term nutrition for adult and pediatric patientsIt is estimated that overthousand feeding tubes are placed in pediatric patients in the US annuallyHoweverthese patients frequently experience complications associated with PG tube placementLate ...
SBIR Phase II 2017 Department of Health and Human Services